echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet respir med: Tepotinib combines gifitinib to treat EGFR-Met mutant non-small cell lung cancer

    Lancet respir med: Tepotinib combines gifitinib to treat EGFR-Met mutant non-small cell lung cancer

    • Last Update: 2020-06-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Tepotinib, a highly selective oral MET inhibitor, recently examined the efficacy and safety of Tepotinib-gifitinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC), who resisted EGFR inhibitors due to MET overexpression or amplificationin SIGHT study was conducted in adult patients (age 18 years) of 1b/2, multicenter, randomized trials, advanced or metastatic NSCLCIn stage 1b, patients take tepotinib 300 mg or 500 mg combined with gifitinib 250 mg once dailyIn the second stage, Patients with EGFR mutation, T790M negative, MET overexpression or amplification of NSCLC were randomly assigned to tepotin-combined gifitini therapy or standard platinum double chemotherapyThe main endpoint of the study was progressionless survival (PFS)Secondary endpoints include total survival (OS) and security18 patients received a Phase 1b study (300mg Tepotinib group n s 6; 500mg Tepotinib group n s 12), 55 patients received Phase II study (Tepotinib combined gifedinib group n s 31; chemotherapy group n s 24)No dose-restricted toxicity was observed in stage 1b, using Tepotinib 500mg as a Phase II doseIn phase II, the median PFS in the Tepotinib union gifitinib group was 4.9 months and the chemotherapy group was 4.4 months (risk ratio of HR.67)The median OS in the Tepotinib union giofinib group was 17.3 months and the chemotherapy group was 18.7 months (HR:0.69)In high (IHC3-plus) MET over expression (n-34; median PFS: 8.3 months vs4.4 months; HR: 0.35, median OS: 37.3 months vs17.September; HR:0.33) or MET amplification (n-19) ;Median PFS: 16.June vs 4.2 months; HR: 0.13, median OS: 37.3 months vs 13.1 month; HR: 0.08) in patients, Teinpot ib's PFS and OS in the Gifitinib treatment group were significantly better than chemotherapyThe most common treatment-related adverse events of level 3 and above were elevated concentrations of amylase (16%) and lipase (13%) in the combined treatment group, anemia (30%) and decreased neutrophil count (13%) in the chemotherapy groupstudies suggest that Tepotinib and giffeitinib have better therapeutic effects on Patients with EGFR mutation and MET amplification of NSCLC compared to chemotherapy
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.